neoplasm
• mice develop mammary tumors but tumor burden is reduced compared to the other transgenic lines, with the majority of mice harboring only a single tumor
• Kras activating mutations are seen in 22.2% of tumors
• majority of tumors are either squamous or epithelial-mesenchymal-transition (EMT) type tumors but microacinar, papillary, solid, and mixed type tumors are also seen
• EMT subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
|
integument
• mice develop mammary tumors but tumor burden is reduced compared to the other transgenic lines, with the majority of mice harboring only a single tumor
• Kras activating mutations are seen in 22.2% of tumors
• majority of tumors are either squamous or epithelial-mesenchymal-transition (EMT) type tumors but microacinar, papillary, solid, and mixed type tumors are also seen
• EMT subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
|
endocrine/exocrine glands
• mice develop mammary tumors but tumor burden is reduced compared to the other transgenic lines, with the majority of mice harboring only a single tumor
• Kras activating mutations are seen in 22.2% of tumors
• majority of tumors are either squamous or epithelial-mesenchymal-transition (EMT) type tumors but microacinar, papillary, solid, and mixed type tumors are also seen
• EMT subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
breast cancer | DOID:1612 |
OMIM:114480 |
J:193362 |